Podcast
Questions and Answers
What is Neulasta® indicated for?
What is Neulasta® indicated for?
Which of the following is/are true about Neulasta® dosing and administration? (Select all that apply)
Which of the following is/are true about Neulasta® dosing and administration? (Select all that apply)
How is Neulasta supplied? (Select all that apply)
How is Neulasta supplied? (Select all that apply)
A healthcare provider must fill the on-body injector for Neulasta® using the prefilled syringe.
A healthcare provider must fill the on-body injector for Neulasta® using the prefilled syringe.
Signup and view all the answers
Approximately ___ hours after the OBI for Neulasta® is applied, Neulasta® will be delivered over approximately ___ minutes.
Approximately ___ hours after the OBI for Neulasta® is applied, Neulasta® will be delivered over approximately ___ minutes.
Signup and view all the answers
Please select the TRUE statements regarding Neulasta®.
Please select the TRUE statements regarding Neulasta®.
Signup and view all the answers
Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.
Neulasta® is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.
Signup and view all the answers
What are the Warnings and Precautions for Neulasta®?
What are the Warnings and Precautions for Neulasta®?
Signup and view all the answers
What are the most common adverse reactions occurring in >5% of patients in pegfilgrastim trials?
What are the most common adverse reactions occurring in >5% of patients in pegfilgrastim trials?
Signup and view all the answers
Which statements regarding the use of Neulasta® in pregnant women are true?
Which statements regarding the use of Neulasta® in pregnant women are true?
Signup and view all the answers
No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients who received Neulasta®.
No overall differences in safety or effectiveness were observed between patients aged 65 and older and younger patients who received Neulasta®.
Signup and view all the answers
In the mechanism of action of Neulasta®, pegfilgrastim is a _____ that acts on _____ by binding to specific cell surface receptors, thereby stimulating _____, _____, _____, and _____.
In the mechanism of action of Neulasta®, pegfilgrastim is a _____ that acts on _____ by binding to specific cell surface receptors, thereby stimulating _____, _____, _____, and _____.
Signup and view all the answers
Neutrophil receptor binding is an important component of the clearance of pegfilgrastim.
Neutrophil receptor binding is an important component of the clearance of pegfilgrastim.
Signup and view all the answers
What is the half-life of Neulasta® after subcutaneous injection?
What is the half-life of Neulasta® after subcutaneous injection?
Signup and view all the answers
In Clinical Studies 1 and 2, both studies met the major efficacy outcome measure.
In Clinical Studies 1 and 2, both studies met the major efficacy outcome measure.
Signup and view all the answers
Study Notes
Neulasta Indications and Administration
- Neulasta® decreases the incidence of infection, specifically febrile neutropenia, in non-myeloid malignancy patients undergoing myelosuppressive therapies.
- It is not meant for mobilizing peripheral blood progenitor cells for stem cell transplantation.
- Administer a single subcutaneous injection of 6 mg once per chemotherapy cycle.
- Do not administer Neulasta® between 14 days before and 24 hours after cytotoxic chemotherapy.
Neulasta Drug Supply and Usage
- Supplied in a prefilled single-dose syringe containing 6 mg of pegfilgrastim and a 27-gauge, ½-inch needle with an UltraSafe® Needle Guard.
- The syringe contains 0.64 mL of solution, delivering 6 mg/0.6 mL when used with the on-body injector (OBI).
- The OBI will deliver Neulasta® approximately 27 hours after application for a duration of 45 minutes.
- The prefilled syringe in the Neulasta® Onpro® kit is exclusively for use with the OBI.
Contraindications and Warnings
- Neulasta® is contraindicated for patients with a history of severe allergic reactions to pegfilgrastim or filgrastim, including anaphylaxis.
- Warnings include risks of splenic rupture, Acute Respiratory Distress Syndrome (ARDS), serious allergic reactions, and potential stimulatory effects on malignant cells.
- Caution advised for use in patients with sickle cell disorders and those experiencing glomerulonephritis.
Adverse Reactions and Efficacy
- The most common adverse reactions occurring in more than 5% of patients include bone pain and extremity pain.
- No significant safety or effectiveness differences noted between patients aged 65 and older and younger patients receiving Neulasta®.
- Neulasta® has a half-life ranging from 15 to 80 hours after subcutaneous injection.
Pregnancy and Mechanism of Action
- Classified as Pregnancy Category C; benefits must justify risks during pregnancy with no well-controlled studies available.
- A pregnancy registry exists for women treated with Neulasta® who become pregnant.
- Mechanism of action involves pegfilgrastim acting as a colony-stimulating factor for hematopoietic cells, stimulating proliferation, differentiation, commitment, and functional activation.
- Neutrophil receptor binding is a key factor in the pharmacokinetics and clearance of pegfilgrastim, with serum clearance linked to neutrophil count.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on Neulasta® and its therapeutic indications. This quiz covers essential information regarding its use in oncology, specifically related to febrile neutropenia in cancer patients. Explore the significance of Neulasta in treatment plans and its limitations.
